Process for the production of an abuse-proofed dosage form

a technology of dosage form and production process, which is applied in the direction of biocide, heterocyclic compound active ingredients, drug compositions, etc., can solve the problems of inability to actually perform safe administration and the inability to extract active ingredients from there, etc., and achieve the effect of intense negative effect and no negative

Inactive Publication Date: 2008-12-18
GRUNENTHAL GMBH
View PDF108 Cites 53 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0110]If components (c) and/or (d) and/or (f) are present in the dosage form obtained according to the invention, care must be taken to ensure that they are formulated in such a manner or are present in such a low dose that, when correctly administered, the dosage form is able to bring about virtually no effect which impairs the patient or the efficacy of the active ingredient.
[0111]If the dosage form obtained according to the invention contains component (d) and/or (f), the dosage must be selected such that, when correctly orally administered, no negative effect is caused. If, however, the intended dosage is exceeded in the event of abuse, nausea or an inclination to vomit or a bad flavour are produced. The particular quantity of component (d) and/or (f) which can still be tolerated by the patient in the event of correct oral administration may be determined by the person skilled in the art by simple preliminary testing.
[0112]If, however, i...

Problems solved by technology

If comminution is inadequate, parenteral, in particular intravenous, administration cannot actually be performed safely or extraction...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for the production of an abuse-proofed dosage form
  • Process for the production of an abuse-proofed dosage form

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0159]

Per tabletComplete batchTramadol HCl100.0mg1495.0gPolyethylene oxide,167.8mg2508.6gMW 7 000 000(Polyox WSR 303 from Dow)Hydroxypropylmethylcellulose33.5mg500.8g(Hypromellose 100 000 mPa)Butyihydroxytoluene (BHT)0.2mg3.0gTotal mass300.5mg4507.4g

[0160]The stated quantity of BHT was dissolved in ethanol (96%), such that a 7.7% (mass / mass) ethanolic solution was obtained. This was mixed initially with 150 g of polyethylene oxide in a high speed mixer for 30 minutes and then the remaining quantity of polyethylene oxide was added and stirring continued for a further 30 minutes. The composition was dried for 12 h at 40° C.

[0161]All the further components were added and mixed for 15 min in a free-fall mixer. The powder mixture was divided between moulds, each having a diameter of 13 mm and a depth of 6 mm. Using a syringe with cannula, the mixture was suspended in each case in 0.5 ml of 96% ethanol and then in each case combined with 0.5 ml of distilled water After 24 hours swelling t...

example 2

[0165]

Powder mixtureComplete batchPer tabletTramadol HCl100.1g100mgPolyethylene oxide300.0g299.7mgMW 5000 000(Polyox WSR Coagulant,from Dow),Hydroxypropylmethylcellulose50.05g50.0mg(Hypromellose 100 000 mPa)Butylhydroxytoluene (BHT)0.25g0.25mgFoam0.250g0.25mgHydroxypropylmethylcellulose(Hypromellose 100 000 mPa)Dist. water49.8g

[0166]The powder mixture was first produced as stated in Example 1.

[0167]The foam was produced by dissolving the stated quantity of Hypromellose in distilled water. A foam was then produced using a high performance homogeniser (IKA Ultraturrax 25 Basic) by stirring initially for 2 minutes at level 1, then for 2 minutes with a mixer / granulator at level 2 and finally for 3 minutes at level 3. The powder mixture was slowly added to the foam with constant stirring in a mixer (Kenwood Major Classic 25 Basic).

[0168]The granulated mixture was then dried for 24 hours—at 40° C. and, after being passed through a screen (from Frewitt, model GLA-A-ORV) with 1 mm orifices,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Forceaaaaaaaaaa
Massaaaaaaaaaa
Structureaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a process for the production of an abuse-proofed dosage form containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer (C) with a breaking strength of at least 500 N, wherein the formulation mixture is combined with a solvent for the polymer (C) at least in quantities such that the formulation mixture is at least uniformly moistened, the at least moistened composition is optionally divided into sub-portions, dried and shaped to yield the dosage form.

Description

[0001]The present invention relates to a process for the production of an abuse-proofed solid dosage form, in which there is added to a formulation mixture containing, one or more active ingredients with potential for abuse (A) and optionally physiologically acceptable auxiliary substances (B) and at least one synthetic or natural polymer (C), which exhibits a breaking strength of at least 500 N,[0002]a) a solvent for the polymer (C) at least in quantities such that the formulation mixture is uniformly moistened,[0003]b) the composition which has been at least moistened in this manner is optionally divided into sub-portions,[0004]c) the portion(s) are dried and[0005]d) shaped to yield the dosage formBACKGROUND OF THE INVENTION[0006]Many pharmaceutical active ingredients, in addition to having excellent activity in their appropriate application, also have potential for abuse, i.e. they can be used by an abuser to bring about effects other than those intended.[0007]Opiates, for exampl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/20A61K31/485A61P25/04
CPCA61K9/1694A61K31/135A61K9/2054A61K9/2027A61K31/485A61P25/04A61K9/2095A61K9/2031A61K31/05A61K9/2013
Inventor ARKENAU-MARIC, ELISABETHBARTHOLOMAUS, JOHANNES
Owner GRUNENTHAL GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap